Teva Pharmaceutical Statistics

Total Valuation

Teva Pharmaceutical has a market cap or net worth of $36.82 billion. The enterprise value is $50.28 billion.

Market Cap	36.82B
Enterprise Value	50.28B

Important Dates

The next confirmed earnings date is Wednesday, April 29, 2026, before market open.

Earnings Date	Apr 29, 2026
Ex-Dividend Date	n/a

Share Statistics

Teva Pharmaceutical has 1.16 billion shares outstanding. The number of shares has increased by 2.83% in one year.

Current Share Class	n/a
Shares Outstanding	1.16B
Shares Change (YoY)	+2.83%
Shares Change (QoQ)	+0.77%
Owned by Insiders (%)	0.46%
Owned by Institutions (%)	69.36%
Float	1.08B

Valuation Ratios

The trailing PE ratio is 25.83 and the forward PE ratio is 11.67. Teva Pharmaceutical's PEG ratio is 2.79.

PE Ratio	25.83
Forward PE	11.67
PS Ratio	2.12
Forward PS	2.16
PB Ratio	4.54
P/TBV Ratio	n/a
P/FCF Ratio	31.88
P/OCF Ratio	22.20
PEG Ratio	2.79

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.15, with an EV/FCF ratio of 43.80.

EV / Earnings	35.66
EV / Sales	2.91
EV / EBITDA	10.15
EV / EBIT	12.72
EV / FCF	43.80

Financial Position

The company has a current ratio of 1.04, with a Debt / Equity ratio of 2.18.

Current Ratio	1.04
Quick Ratio	0.54
Debt / Equity	2.18
Debt / EBITDA	3.39
Debt / FCF	15.01
Interest Coverage	4.31

Financial Efficiency

Return on equity (ROE) is 20.79% and return on invested capital (ROIC) is 18.08%.

Return on Equity (ROE)	20.79%
Return on Assets (ROA)	6.17%
Return on Invested Capital (ROIC)	18.08%
Return on Capital Employed (ROCE)	14.48%
Weighted Average Cost of Capital (WACC)	7.09%
Revenue Per Employee	$508,336
Profits Per Employee	$41,532
Employee Count	33,950
Asset Turnover	0.43
Inventory Turnover	2.69

Taxes

Income Tax	-180.00M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +112.64% in the last 52 weeks. The beta is 0.76, so Teva Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.76
52-Week Price Change	+112.64%
50-Day Moving Average	31.20
200-Day Moving Average	25.59
Relative Strength Index (RSI)	54.97
Average Volume (20 Days)	4,680,430

Short Selling Information

The latest short interest is 29.74 million, so 2.57% of the outstanding shares have been sold short.

Short Interest	29.74M
Short Previous Month	37.62M
Short % of Shares Out	2.57%
Short % of Float	n/a
Short Ratio (days to cover)	5.16

Income Statement

In the last 12 months, Teva Pharmaceutical had revenue of $17.26 billion and earned $1.41 billion in profits. Earnings per share was $1.21.

Revenue	17.26B
Gross Profit	8.94B
Operating Income	3.95B
Pretax Income	1.24B
Net Income	1.41B
EBITDA	4.95B
EBIT	3.95B
Earnings Per Share (EPS)	$1.21

Full Income Statement

Balance Sheet

The company has $3.56 billion in cash and $17.23 billion in debt, giving a net cash position of -$13.67 billion or -$11.74 per share.

Cash & Cash Equivalents	3.56B
Total Debt	17.23B
Net Cash	-13.67B
Net Cash Per Share	-$11.74
Equity (Book Value)	7.91B
Book Value Per Share	6.88
Working Capital	490.00M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $1.65 billion and capital expenditures -$501.00 million, giving a free cash flow of $1.15 billion.

Operating Cash Flow	1.65B
Capital Expenditures	-501.00M
Depreciation & Amortization	1.00B
Net Borrowing	-1.81B
Free Cash Flow	1.15B
FCF Per Share	$0.99

Full Cash Flow Statement

Margins

Gross margin is 51.79%, with operating and profit margins of 22.90% and 8.17%.

Gross Margin	51.79%
Operating Margin	22.90%
Pretax Margin	7.17%
Profit Margin	8.17%
EBITDA Margin	28.71%
EBIT Margin	22.90%
FCF Margin	6.65%

Dividends & Yields

Teva Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.83%
Shareholder Yield	-2.83%
Earnings Yield	3.85%
FCF Yield	3.14%

Dividend Details

Analyst Forecast

The average price target for Teva Pharmaceutical is $38.63, which is 22.17% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$38.63
Price Target Difference	22.17%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.

Last Split Date	Jul 1, 2004
Split Type	Forward
Split Ratio	2:1

Scores

Teva Pharmaceutical has an Altman Z-Score of 0.68 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.68
Piotroski F-Score	8